{"description":"Adverse events collected as per protocol using CTCAE version 4.0","eventGroups":[{"deathsNumAffected":7,"deathsNumAtRisk":25,"description":"Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nTrametinib: Given PO\n\nUprosertib: Given PO","id":"EG000","otherNumAffected":25,"otherNumAtRisk":25,"seriousNumAffected":15,"seriousNumAtRisk":25,"title":"Treatment (Trametinib, Akt Inhibitor GSK2141795)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Platelet count decreased","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":25}],"term":"thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Nausea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":25}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Rash","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":25}],"term":"Rash"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Sepsis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":25}],"term":"Sepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Lung infection","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}],"term":"Lung infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Intracranial hemorrhage","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}],"term":"Intracranial hemorrhage"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)-OTHER, PROGRESSIVE DISEASE","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}],"term":"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Confusion","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}],"term":"Confusion"}],"timeFrame":"From treatment start until 4 weeks after treatment end or death (whichever occurs first), for each patient, an average of 1 year."}